English
Home > Products > CAS:1083076-69-0

China CAS:1083076-69-0 Manufacturer

We insist over the principle of enhancement of 'High high quality, Efficiency, Sincerity and Down-to-earth working approach' to offer you with superb assistance of processing for CAS:1083076-69-0, We have exported to more than 40 countries and regions, which have gained fantastic popularity from our costumers everywhere in the globe.
CAS:1083076-69-0, We give good quality but unbeatable low price and the best service. Welcome to post your samples and color ring to us .We are going to produce the items according to your request. If you are interested in any solutions we provide, remember to feel free to contact us directly by mail, fax, telephone or internet. We have been here to answer your questions from Monday to Saturday and looking forward to cooperating with you.

Related Products

Hot Products

  • Budesonide

    Budesonide

    Budesonide has USP, EP specifications. CEP, GMP and FDA approved.

    CAS:51333-22-3

  • Levonorgestrel

    Levonorgestrel

    Levonorgestrel has speficications of CP/EP/USP. DMF,GMP and CEP available.

    CAS:797-63-7

  • Triacetyl-ganciclovir

    Triacetyl-ganciclovir

    Triacetyl-ganciclovir is a Ganciclovir derivative.

    CAS:86357-14-4

  • Oxcarbazepine

    Oxcarbazepine

    Oxcarbazepine has CP, EP and USP specifications. CEP and DMF available, GMP approved.

    CAS:28721-07-5

  • Epiandrosterone

    Epiandrosterone

    Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).

    CAS:481-29-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • 2019 CPhI China Exhibition Shanghai

    June 2019
    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • 2023 See us at DCAT Week, CPHI and API exhibition!

  • 2024 CPhI Exhibition Shanghai

    In 2024, CPhI China will continue to be a unique opportunity for global pharmaceutical companies, manufacturers and suppliers. We will be waiting for you at the W1G20 booth on time to explore and interpret new trends in the pharmaceutical industry and interact with each other to further expand their business cooperation and various business opportunities. See you in Shanghai!

  • Visit us at Milan CPHI - Booth 3A65!

    We're looking forward to welcoming you!

  • Is This the Best Intermediate Course for Practical Project Experience

    Ever found yourself scrolling through endless course listings, wondering which one actually bridges the gap between theory and a tangible, portfolio-worthy project? I’ve been there. With two decades in the tech industry, I’ve seen countless learners in the Intermediates Category hit a frustrating plateau. They know the basics but struggle to apply them convincingly in real-world scenarios. This is the core pain point we aimed to solve.

  • Join Us at Booth N25 for CPHI Korea 2025 in Seoul

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept